ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Psychiatry · J Affect Disord · 2026-10-06

Cross-sectional secondary analysis of screening data from an ongoing trial: among 108 euthymic adults with bipolar disorder, self-reported regular exercisers had higher SCIP total cognitive scores than non-exercisers (64.63 vs 56.50; d=0.95). Causality cannot be inferred.

Secondary analysisn = 108
Belizario et al. Cognitive performance and self-reported physical exercise in bipolar disorder: A cross-sectional analysis of pre-randomization screening data from an ongoing randomized controlled trial
Psychiatry · J Affect Disord · 2026-09-30

Network meta-analysis of RCTs in acute depression with mixed features: lurasidone 60-80 mg/day, lumateperone 42 mg/day and asenapine 15 mg/day beat placebo on symptoms in bipolar depression (22 studies, 5241 participants); lurasidone 40 mg/day did in major depression.

Meta-analysisn = 7,055
Fornaro et al. Pharmacological interventions for acute major depression and bipolar depression with mixed features: A systematic review and dose-related network meta-analysis across different age groups
Psychiatry · Bipolar Disord · 2026-08-01

In a pilot double-blind crossover trial of 18 people with bipolar disorder, 30-min theta-gamma tACS was as tolerable as sham (no side-effect differences); effects on discriminability, theta power and PAC were small but consistently favoured active stimulation.

RCTn = 18
Kraft et al. Enhancing Affective Cognitive Control in Bipolar Disorder Using Transcranial Alternating Current Stimulation: A Double-Blind, Randomized, Sham-Controlled Clinical Trial and Proof of Concept Study
Psychiatry · J Affect Disord · 2026-07-29

Network meta-analysis of 113 RCTs (20,666 participants) in acute bipolar mania: many drugs and doses, including risperidone, haloperidol, olanzapine, lithium and valproate, cut manic symptoms vs placebo; no significant differences for response, acceptability or tolerability.

Meta-analysisn = 20,666
Fornaro et al. Efficacy, acceptability, and related outcomes of pharmacological interventions for acute bipolar mania: a systematic review and dose-related network meta-analysis across different age groups
Psychiatry · J Affect Disord · 2026-07-07

In an exploratory open-label trial of 185 patients with primary insomnia or depressive/bipolar depressive episodes with insomnia, dimdazenil 2.5 mg gave a mean subjective total sleep time 7.36 min longer than midazolam 15 mg at day 14; no significance test was reported.

RCTn = 185
Dun et al. Efficacy and safety of Dimdazenil in primary insomnia and depressive episodes/bipolar depressive episode with insomnia: A post-marketing, randomized, open-label, positive-controlled study

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.